Epithalon

Chemical identity

Epithalon is a four-residue peptide — alanine, glutamic acid, aspartic acid, glycine — synthesised as a defined analogue of Epithalamin, a crude pineal gland extract studied in the Soviet Union from the 1970s. It is the smallest compound listed on this site.

Two acidic residues out of four make this a strongly anionic peptide at physiological pH, which governs both its solubility behaviour and its chromatographic retention. It elutes early on reversed-phase columns, and methods developed for more hydrophobic peptides will not retain it.

Mechanism in research models

The central published claim is induction of telomerase activity, with reported telomere elongation in cultured human somatic cells. The proposed mechanism is transcriptional — direct or indirect upregulation of the TERT catalytic subunit — rather than any enzymatic activity of the peptide itself.

A secondary body of work describes sequence-specific interaction with DNA and modulation of gene expression, and effects on pineal melatonin output in aged animals. The proposed DNA-binding mechanism for a four-residue peptide is unusual and has not been independently confirmed by structural methods.

Investigators should note that the mechanistic literature is thin relative to the strength of the claims made for this compound. Telomerase induction is a significant assertion and warrants a positive control and independent assay.

What the literature establishes

Almost the entire evidence base originates from one research group — the St Petersburg Institute of Bioregulation and Gerontology — over several decades. Reported findings include extended lifespan in mice and rats, reduced spontaneous tumour incidence, and improved outcome measures in long-term human observational studies.

Independent replication outside that group is very limited. This is the single most important caveat for anyone designing work around Epithalon: a large, internally consistent literature from one source is a weaker foundation than a small one from several.

Treat the telomerase and lifespan findings as hypotheses to be tested rather than as background facts, and build replication of the core in-vitro result into any study plan before extending it.

Handling, reconstitution and storage

Lyophilised material is typically held sealed and desiccated at −20 °C; the validated condition is the one on the lot documentation. Short peptides without secondary structure are relatively robust in the dry state.

Readily water-soluble. The two carboxylate side chains give good aqueous solubility across a wide pH range; no solvent assistance is required.

Aliquot and freeze after reconstitution. The tetrapeptide is susceptible to aminopeptidase cleavage in any preparation containing biological material, so solutions intended for cell work should be prepared fresh.

Analytical documentation

Require RP-HPLC purity and an observed mass of 390.35. At this molecular weight, mass spectrometry is unambiguous and there is no excuse for an absent or vague identity confirmation.

Note the chromatography caveat: Epithalon's early elution means a poorly developed method can push it into the solvent front, where impurities are invisible. Ask what retention time the purity figure was measured at, and be sceptical of a 99% claim from a method that has not been shown to retain the compound.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.